Targeted inhibition of Sur1-regulated channels by the sulfonylurea glibenclamide (also known as glyburide, US adopted name) may offer an effective new treatment option for both ischemic and hemorrhagic forms of stroke. The gene discussed is ABCC8; the disease is stroke disorder.